FDA Grants Accelerated Approval to Sevabertinib for Non-Squamous NSCLC By Ogkologos - November 27, 2025 193 0 Facebook Twitter Google+ Pinterest WhatsApp It also approved a companion diagnostic device to aid in detecting HER2 tyrosine kinase domain activating mutations Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR Researchers Discover Way to Help Immunotherapy Better Target Solid Tumors Like... January 5, 2021 Cetuximab Outperforms Durvalumab for Head and Neck Cancer When Cisplatin Isn’t... December 19, 2024 Breast Cancer Surgery Choice May Affect Young Survivors’ Quality of Life September 30, 2021 ‘Levelling Up’: What should it mean for cancer? February 2, 2022 Load more HOT NEWS Sotorasib Shows Increase in PFS and a More Favourable Safety Compared... FDA Approves Durvalumab with Chemotherapy for Mismatch Repair Deficient Primary Advanced... UK Clinical Trial Compares E-cigarettes, Nicotine-Replacement Products for Smoking Cessation Does Eating Processed Meat Increase Your Risk for Cancer?
